Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Sophia Zhao"'
Autor:
James E. Dinulos, BA, Qiyu Wang, MD, Sophia Zhao, MD, PhD, Duru Cosar, BS, Ritu Seethapathy, MBBS, Joshua D. Long, BA, Ian Strohbehn, BA, Meghan E. Sise, MD, MS
Publikováno v:
Kidney Medicine, Vol 6, Iss 7, Pp 100835- (2024)
Externí odkaz:
https://doaj.org/article/f63b0696cf134e05a157fe57cb4b6ecd
Autor:
Rituvanthikaa Seethapathy, Qiyu Wang, Sophia Zhao, Ian A Strohbehn, Joshua D Long, James E Dinulos, Destiny Harden, Vinay B Kadiyala, Daiana Moreno, Meghan E Sise
Publikováno v:
PLoS ONE, Vol 18, Iss 2, p e0279765 (2023)
BackgroundChronic kidney disease (CKD) is an important risk factor for mortality from COVID-19. Remdesivir has been shown to shorten time to recovery in patients with severe COVID-19. However, exclusion of patients with severe kidney function impairm
Externí odkaz:
https://doaj.org/article/e2b94e77a15748b9b09c88bdf19de5ef
Autor:
Ignacio A. Portales-Castillo, MD, Cagri Aksu, MD, Sophia Zhao, MD, PhD, Ian Strohbehn, BA, Meghan Sise, MD, Elaine W. Yu, MD, Sagar U. Nigwekar, MD, MMSc.
Publikováno v:
Kidney Medicine, Vol 3, Iss 6, Pp 1112-1115 (2021)
Externí odkaz:
https://doaj.org/article/ee2e57fbd2be4f4b880276afb359e52d
Autor:
Harish Seethapathy, Sophia Zhao, Ian A. Strohbehn, Meghan Lee, Donald F. Chute, Halla Bates, Gabriel E. Molina, Leyre Zubiri, Shruti Gupta, Shveta Motwani, David E. Leaf, Ryan J. Sullivan, Osama Rahma, Kimberly G. Blumenthal, Alexandra-Chloe Villani, Kerry L. Reynolds, Meghan E. Sise
Publikováno v:
Kidney International Reports, Vol 5, Iss 10, Pp 1700-1705 (2020)
Background: Programmed cell death receptor ligand 1 (PD-L1) inhibitors are immune checkpoint inhibitors (ICIs) with a side effect profile that may differ from other classes of ICIs such as those directed against cytotoxic T-lymphocyte−associated pr
Externí odkaz:
https://doaj.org/article/e8904d035ea34b23aca56820cb203d19
Autor:
J. Corey Fowler, Taisa Skubiak, Kirsten Engelhardt, Benjamin Furst, Sophia Zhao, Margaretta Nyilas, Debbie Profit, William Carson
Publikováno v:
Journal of Scientific Innovation in Medicine, Vol 4, Iss 1 (2021)
Objective:Adding to existing challenges in conducting clinical trials, COVID-19 has indefinitely affected modern clinical research. Decentralized clinical trials, using telemedicine and digital technology, may prove critical to the future of clinical
Externí odkaz:
https://doaj.org/article/6ae4dad627b441dd9d7fce83a35c887b
Autor:
Anders H Berg, Mahtab Tavasoli, Agnes S Lo, Sherri-Ann M Burnett-Bowie, Ishir Bhan, S Ananth Karumanchi, Sahir Kalim, Dongsheng Zhang, Sophia Zhao, Ravi I Thadhani
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0254158 (2021)
BackgroundBioavailable 25-hydroxyvitamin D (25OHD) may be a better indicator of vitamin D sufficiency than total 25OHD. This report describes a novel assay for measuring serum bioavailable 25OHD.MethodsWe developed an assay for 25OHD % bioavailabilit
Externí odkaz:
https://doaj.org/article/6090c91ee93c4db39ab2de7fba8ece91
Autor:
Xiaohong Fan, Sahir Kalim, Wenling Ye, Sophia Zhao, Jie Ma, Sagar U. Nigwekar, Kevin E. Chan, Jie Cui, Jianfang Cai, Liang Wang, Wei Heng, Yali Zhou, Ying Sun, Rui Cui, Wei Zhang, Baobao Wang, Qing Dai, Xuewang Li, Ravi Thadhani, Xuemei Li
Publikováno v:
Kidney International Reports, Vol 2, Iss 6, Pp 1042-1049 (2017)
Urinary stone disease (USD) is associated with cardiovascular disease (CVD) in Western populations. However, the prevalence and relationship between USD and CVD risk have not been fully examined in the Chinese population. Methods: We performed a cros
Externí odkaz:
https://doaj.org/article/f6afba462a0d437ea958527768f93591
Autor:
Sahir Kalim, Sophia Zhao, Mengyao Tang, Eugene P. Rhee, Andrew S. Allegretti, Sagar Nigwekar, S. Ananth Karumanchi, James P. Lash, Anders H. Berg
Publikováno v:
Journal of the American Society of Nephrology. 34:876-885
Autor:
Bruce C Tiu, Ian A Strohbehn, Sophia Zhao, Tianqi Ouyang, Paul Hanna, Qiyu Wang, Shruti Gupta, David E Leaf, Kerry L Reynolds, Meghan E Sise
Publikováno v:
The Oncologist.
BackgroundClinical trials of immune checkpoint inhibitors (ICIs) often do not include patients with advanced chronic kidney disease (CKD). We aimed to determine the safety of ICIs in patients with cancer and advanced CKD (stages 4-5 CKD, estimated gl
Publikováno v:
Frontiers in Neuroendocrinology. 70:101067